{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:24:50Z","timestamp":1776853490968,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2021\/CBG0002"],"award-info":[{"award-number":["2021\/CBG0002"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.modpat.2025.100776","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:05:43Z","timestamp":1744628743000},"page":"100776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4415-1500","authenticated-orcid":false,"given":"Jorja","family":"Braden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurudeen A.","family":"Adegoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan W.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P.M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerwin F.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Gyorki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Howle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Wilmott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Pires da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.modpat.2025.100776_bib1","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/pon.4777","article-title":"Using generalized estimating equations and extensions in randomized trials with missing longitudinal patient reported outcome data","volume":"27","author":"Bell","year":"2018","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.modpat.2025.100776_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/mmt.15.38","article-title":"Biology and treatment of BRAF mutant metastatic melanoma","volume":"3","author":"Kong","year":"2016","journal-title":"Melanoma Manag"},{"issue":"8","key":"10.1016\/j.modpat.2025.100776_bib3","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/cancers12082072","article-title":"Age does matter in adolescents and young adults versus older adults with advanced melanoma; a national cohort study comparing tumor characteristics, treatment pattern, toxicity and response","volume":"12","author":"van der Kooij","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.modpat.2025.100776_bib4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ijc.31791","article-title":"Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility","volume":"144","author":"Wilmott","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.modpat.2025.100776_bib5","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.modpat.2025.100776_bib6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.modpat.2025.100776_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.modpat.2025.100776_bib8","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.modpat.2025.100776_bib9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.modpat.2025.100776_bib10","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100776_bib11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100776_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7934","key":"10.1016\/j.modpat.2025.100776_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.modpat.2025.100776_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.modpat.2025.100776_bib15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.modpat.2025.100776_bib16","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2022.40.16_suppl.9503","article-title":"NeoTrio: randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy","volume":"40","author":"Long","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100776_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.modpat.2025.100776_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2025.100776_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.annonc.2024.05.002","article-title":"Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma","volume":"35","author":"Menzies","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2025.100776_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.annonc.2023.06.006","article-title":"Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III\/IV cutaneous melanoma","volume":"34","author":"Sharon","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100776_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100776_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.modpat.2025.100776_bib23","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.modpat.2025.100776_bib24","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/modpathol.2015.110","article-title":"Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases","volume":"28","author":"Kakavand","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100776_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.modpat.2025.100776_bib26","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100776_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2025.100776_bib28","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41591-024-03077-5","article-title":"Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial","volume":"30","author":"Long","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.modpat.2025.100776_bib29","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2025.100776_bib30","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","article-title":"Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma","volume":"32","author":"Rawson","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100776_bib31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/annonc\/mdz019","article-title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response","volume":"30","author":"Stein","year":"2019","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.modpat.2025.100776_bib32","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2025.100776_bib33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.annonc.2020.07.016","article-title":"Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma","volume":"31","author":"Tetzlaff","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2025.100776_bib34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100776_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/biomedicines8070232","article-title":"Sex and gender influences on cancer immunotherapy response","volume":"8","author":"Irelli","year":"2020","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.modpat.2025.100776_bib36","article-title":"SeXX matters in infectious disease pathogenesis","volume":"12","author":"vom","year":"2016","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.modpat.2025.100776_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/intimm\/dxl151","article-title":"Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)","volume":"19","author":"Polanczyk","year":"2007","journal-title":"Int Immunol"},{"issue":"16","key":"10.1016\/j.modpat.2025.100776_bib38","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","article-title":"BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy","volume":"72","author":"Koya","year":"2012","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.modpat.2025.100776_bib39","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.3390\/cancers15184433","article-title":"Sex differences in the efficacy of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a meta-analysis","volume":"15","author":"Suay","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.modpat.2025.100776_bib40","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/molecules24183214","article-title":"Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.modpat.2025.100776_bib41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2025.100776_bib42","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jnci\/djz094","article-title":"Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis","volume":"111","author":"Conforti","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.modpat.2025.100776_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.modpat.2025.100776_bib44","series-title":"Robbins and Cotran Pathologic Basis of Disease","author":"Cotran","year":"2010"},{"issue":"8","key":"10.1016\/j.modpat.2025.100776_bib45","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B cell regulation in cancer and anti-tumor immunity","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.modpat.2025.100776_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.modpat.2025.100776_bib47","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.modpat.2025.100776_bib48","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"7791","key":"10.1016\/j.modpat.2025.100776_bib49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.modpat.2025.100776_bib50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.modpat.2025.100776_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"issue":"7791","key":"10.1016\/j.modpat.2025.100776_bib52","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:00:28Z","timestamp":1762315228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0893395225000729"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100776","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100776"}}